Loading stock data…
GLSI
$23.70+0.08 (+0.34%)
Market ClosedLast close May 1
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Greenwich LifeSciences, Inc. in the Healthcare sector is trading at $23.70. The stock is currently 30% below its 52-week high of $34.10, remaining 39.0% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why GLSI maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.70
Potential Upside
5%
Whystock Fair Value$24.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$47.50+100.4%
Range$45.00 – $50.00
Fundamentals
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunother...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$345.53M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-338.47%
Volume
Today's trading volume
115,527
Recent News
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases
Key Insights Insiders appear to have a vested interest in Greenwich LifeSciences' growth, as seen by their sizeable...
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index up 0.2% and t
Top Midday Gainers
60 Degrees Pharmaceuticals (SXTP) reported Thursday a partnership with Runway Health to boost access
Wall Street Set to Open Higher Thursday as Investors Parse GDP, Unemployment Data, Look Ahead to Inflation Report
US stocks look set to open higher in Thursday's trading session as investors parse gross domestic pr
Investors Await Raft of Key Economic Data as US Futures Rise Thursday Pre-Bell
US stock futures are tracking higher in Thursday's premarket session as investors look ahead to a sl